(Total Views: 1169)
Posted On: 06/12/2020 6:08:44 PM
Post# of 148899
MISSED SOMETHING MAJOR in the exclusion criteria
Note: Subject who were prescribed (1) hydroxychloroquine or chloroquine with or without azithromycin, (2) Remdesivir, (3) convalescent plasma therapy, or (4) immunomodulatory treatments (including but not limited to sarilumab, clazakizumab, tocilizumab, and anakinra) for the off-label treatment of COVID-19 prior to study enrollment may be included and may continue to receive these agents as part of standard-of-care.
Did you see this article?
https://emerginggrowth.com/adam-feuersteins-f...empty-net/
Absolutely nailed this point! Darn good analysis - a must read.
Note: Subject who were prescribed (1) hydroxychloroquine or chloroquine with or without azithromycin, (2) Remdesivir, (3) convalescent plasma therapy, or (4) immunomodulatory treatments (including but not limited to sarilumab, clazakizumab, tocilizumab, and anakinra) for the off-label treatment of COVID-19 prior to study enrollment may be included and may continue to receive these agents as part of standard-of-care.
Did you see this article?
https://emerginggrowth.com/adam-feuersteins-f...empty-net/
Absolutely nailed this point! Darn good analysis - a must read.
(4)
(0)Scroll down for more posts ▼
